Fundraising Fox

Jounce Therapeutics

Cambridge, US · Founded 2012 · Delaware corporation · 2 known investors

jouncetx.com ↗
Biotech

Founders & leadership

KC
Kim C. DrapkinExecutive
AL
Anna L. BarryExecutive
RMRichard Murray
Richard MurrayExecutive

Board

RTRobert Tepper
Robert TepperinBoard directorPartner and co-founder of Third Rock Ventures
CPCary Pfeffer
Cary PfefferinBoard directorInvestor at Third Rock Ventures
RKRobert Kamen
Robert KameninBoard directorVenture Partner at Third Rock Ventures

Investors · 2

Nextech InvestZurich · $648K – $3.2M
Third Rock Venturesreported · 2 sourcesBoston · $100K – $5Mvia Robert Kamen · board

Reported raises · per SEC filings

Form D private placements

$91M disclosed across 2 rounds · 2015–2020

▶$35MraisedOct 2020 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Luis A. Diaz, Jr.Director
  • Duncan HiggonsDirector
  • Robert IannoneDirector
  • Robert KamenDirector
  • Cary PfefferDirector
  • Robert TepperDirector
  • Perry KarsenDirector
  • Elizabeth G. TrehuExecutive Officer
  • Hugh M. ColeExecutive Officer
  • Kimberlee C. DrapkinExecutive Officer
  • Richard MurrayExecutive Officer, Director
  • Barbara DuncanDirector
Offering amount
$35M
Amount sold
$35M
First sale
Oct 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$56MraisedApr 2015 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert TepperDirector
  • Kim C. DrapkinExecutive Officer
  • Anna L. BarryExecutive Officer
  • Richard MurrayExecutive Officer, Director
  • Cary G. PfefferDirector
  • Robert KamenDirector
Offering amount
$56M
Amount sold
$56M
First sale
Apr 2015
Incorporated
Corporation, Delaware, 2012
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Jounce Therapeutics announces merger with Redx after laying off more than half of staffmmm-online.com · Feb 2023If You Had Bought Jounce Therapeutics (NASDAQ:JNCE) Stock A Year Ago, You'd Be Sitting On A 56% Loss, Today - Simply Wall St Newssimplywall.st · May 2019​Cambridge’s Jounce Therapeutics raises hopes as first Massachusetts biotech of 2017 to go public - Boston Business Journalbizjournals.com · Jan 2017Immuno-oncology company Jounce receives $56m jolt - Global Venturingglobalventuring.com · Apr 2015Jounce Therapeutics' $56M Series B to build out "atlas of human cancers," diversify immunotherapy offerings - MedCity Newsmedcitynews.com · Apr 2015Jounce Therapeutics Raises $47M in Series A Financing from Third Rock Ventures - FinSMEsfinsmes.com · Feb 2013

Frequently asked questions

Who are Jounce Therapeutics's investors?
Jounce Therapeutics's investors include Nextech Invest, Third Rock Ventures.
How much funding has Jounce Therapeutics raised?
Jounce Therapeutics has disclosed $91M raised across 2 rounds.
Where is Jounce Therapeutics headquartered?
Jounce Therapeutics is headquartered in Cambridge, US.